摘要目的:探讨奥司他韦胶囊联合金叶败毒颗粒治疗甲型H1N1流感的疗效和安全性。方法:204例患者采用系统随机化法按患者就诊卡的单双号随机分为实验组(100例)和对照组(104例),对照组患者给予磷酸奥司他韦胶囊口服(75mg/次,每天2次),实验组在磷酸奥司他韦治疗基础上给予金叶败毒颗粒温水冲服(每次10g,每天3次),两组患者均连续治疗5d,监测两组患者治疗前后的血常规、C-反应蛋白(CRP)及肝肾功能,观察各组患者的疗效及不良反应。结果:实验组和对照组疗效比较,其中第3天体温正常率(91% vs 79.8%)、第3天及第5天的临床症状缓解率(61% vs 47%,79% vs 61%)、总的治愈率(40% vs 26%)这几项指标实验组明显好于对照组,其差异有显著意义(P<0.05);实验组患者的总无效低于对照组(3% vs 7.7%),而总的有效率高于对照组(97% vs 92.3%),均无统计学意义(P>0.05)。实验组和对照组患者的第5天体温正常率(97% vs 94.2%)、病情恶化率(2% vs 5.8%)及第 5 天 鼻拭子病毒转阴率(99% vs 97.1%)没有显著差异(P>0.05)。2 组患者总的不良反应率(24% vs 22.1%)无显著差异(P>0.05)。治疗前后 两 组患者的白细胞(WBC)、单核细胞百分比(M%)及治疗前2 组患者的 CRP 没有显著差异(P>0.05),而治疗后实验组患者的 CRP 显著低于对照组[(11.9±3.6)mg/L vs(14.2±4.3)mg/L](P<0.05)。治疗前后 两 组患者的肝肾功能变化都没有显著差异(P>0.05)。结论:奥司他韦胶囊联合使用金叶败毒颗粒治疗甲型H1N1流感能够更有效地改善临床症状,且不会增加不良反应。
Abstract：Objective: To investigate the efficacy and safety of oseltamivir capsules combined with Jinye Baidu granules in the treatment of influenza A (H1N1). Methods: 204 patients with influenza A (H1N1) were randomly divided into trial group (100 cases) and control group (104 cases). Patients in the control group were administered with oseltamivir phosphate capsules orally (75 mg each time, twice a day) ; the trial group received oseltamivir phosphate capsules combined with Jinye baidu Granules (10g each time, 3 times a day) for oral treatment. Both groups of patients were treated continuously for 5 days. Blood routine, C-reactive protein (CRP) and liver and kidney function were measured in 2 groups before and after treatment. The efficacy and adverse reactions of each group of patients were observed. Results: The therapeutic effect of the experimental group comparing with that of the control group, the normal temperature rate was 91% vs 79.8% on the third day, the clinical symptom relief rate was 61% vs 47%, 79% vs 61% on the third and fifth day, and the total cure rate was 40% vs 26%. These indexes in the experimental group were significantly better than those in the control group (P < 0.05) ; The total ineffectiveness of the experimental group was lower than that of the control group (3% vs 7.7%), and the overall effective rate was higher than that of the control group (97% vs 92.3%), but the difference was not statistically significant (P>0.05). There were no significant differences in the rate of temperature recovery (97% vs 94.2%), deterioration rate (2% vs 5.8%) and negative rate of nasal swab virus (99% vs 97.1%) between the two groups on the 5th day (P>0.05). The overall adverse reaction rate between the two groups was compared (24% vs 22.1%) and no significant difference was found (P>0.05). There were no significant differences in white blood cells (WBC), percentage of monocytes (M%), liver and kidney function between the two groups before and after treatment (P>0.05). No significant difference was observed in C-reactive protein (CRP) between the two groups before treatment, but CRP in the trial group was significantly lower than that in the control group after treatment[ (11.9±3.6) mg/L vs (14.2±4.3) mg/L] (P<0.05). Conclusion: The combination of oseltamivir capsule and Jinye baidu granule can improve the clinical symptoms of influenza A (H1N1) more effectively without increasing adverse reactions.
罗豫川, 胡克, 鲁丽. 奥司他韦胶囊联合金叶败毒颗粒治疗甲型H1N1流感的疗效研究[J]. 河北医学, 2020, 26(3): 379-383.
LUO Yuchuan, HU Ke, LU Li. Effect of Oseltamivir Capsule Combined with Jinye Baidu Granule on Influenza A (H1N1). HeBei Med, 2020, 26(3): 379-383.
[1] Uyeki T.Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1)[J].N Engl Med,2009,361(23):e110. [2] 中华人民共和国卫生部.甲型H1N1流感的诊疗方案(2010年版)[J].中华结核和呼吸杂志,2011,31(2):81~84. [3] Cao B,Li XW,Mao Y,et a1.Clinical features of the initial cases of 2009 pandemic influenza A(H1N1)virus infection in China[J].N Engl Med,2009,361(20):2507~2517. [4] 朱琳枫,鲍欣欣,姚辉,等.金银花和鱼腥草抑制甲型流感病毒体外复制研究[J].国际检验医学杂志,2018,39(4):485~486. [5] 陈丽,顾燕.金银花注射液抗流感病毒作用的实验研究[J].现代医药卫生,2016,32(2):175~177. [6] 王晓丹,夏晓玲,赵玉娇,等.蒲公英有机萃取物的抗甲型H1N1流感病毒作用[J].中国现代应用药学,2015,32(12):1423~1427. [7] Ashish P novadiya, Manish J arvaliya, Rajesh A hah,et al.Adverse drug reaction profile of oseltamivir in Indian population: a prospective observational study[J]. Indian Pharmacol,2011,43(3): 258~261.
2020, Vol. 26 
冀公网安备13080202000677号